The use of “Acellbia” – a biosimilar of rituximab in systemic sclerosis
Introduction. The possibilities of modern therapy for systemic sclerosis (SSc) remains limited, since most of the used drugs do not have a diseasemodifying effect. This encourages the study of new approaches that potentially affect the fundamental pathological processes underlying the disease. One e...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Russo |
| Baskı/Yayın Bilgisi: |
IMA PRESS LLC
2023-08-01
|
| Seri Bilgileri: | Научно-практическая ревматология |
| Konular: | |
| Online Erişim: | https://rsp.mediar-press.net/rsp/article/view/3403 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|